Review Special Issues

No Reflow-phenomenon: from Current State of the Art to Future Perspectives

  • Received: 29 June 2015 Accepted: 24 November 2015 Published: 30 November 2015
  • Early and successful myocardial reperfusion with primary percutaneous coronary intervention (pPCI) is the optimal therapy for patients presenting with ST segment elevation myocardial infarction (STEMI). Despite successful epicardial reopening of the infarct related artery, myocardial perfusion may not be restored in up to 40-50% of patients. This phenomenon, referred to as no-reflow (NR), recognizes several pathogenetic components including distal atherothrombotic embolization, ischaemic injury, reperfusion damage, intramyocardial hemorrhage and individual susceptibility of coronary microcirculation. However the complexity of pathogenesis remains still unclear. Moreover, cause NR plays a crucial role in patients prognosis, accurate detection is critical and multiple novel diagnostic modalities has been recently assessed.The NR phenomenon represents a challenge in the management of STEMI patients and has recently captured a growing interest of both basic scientists and interventional cardiologists. Although relevant efforts to transfer into real world practice new therapeutic strategies, to date there is still weak evidence of clinical improvement in this setting. Several strategies of prevention and treatment of NR have been proposed in the clinical arena including pharmacological and mechanical interventions. Nevertheless, the complexity of the phenomenon makes extremely unlikely for a single therapy to be effective. Understanding the interaction between the components of this pathway, along with exploring newer and more effective agents may enable patients to be treated with the most appropriate therapy.

    Citation: Valeria Paradies, Filippo Masi, Francesco Bartolomucci, Alfredo Marchese, Armando Liso, Fabrizio Resta, Stefano Favale, Martino Pepe. No Reflow-phenomenon: from Current State of the Art to Future Perspectives[J]. AIMS Medical Science, 2015, 2(4): 374-395. doi: 10.3934/medsci.2015.4.374

    Related Papers:

    [1] Sandesh Athni Hiremath, Christina Surulescu, Somayeh Jamali, Samantha Ames, Joachim W. Deitmer, Holger M. Becker . Modeling of pH regulation in tumor cells: Direct interaction between proton-coupled lactate transporters and cancer-associated carbonicanhydrase. Mathematical Biosciences and Engineering, 2019, 16(1): 320-337. doi: 10.3934/mbe.2019016
    [2] Allen L. Nazareno, Raymond Paul L. Eclarin, Eduardo R. Mendoza, Angelyn R. Lao . Linear conjugacy of chemical kinetic systems. Mathematical Biosciences and Engineering, 2019, 16(6): 8322-8355. doi: 10.3934/mbe.2019421
    [3] OPhir Nave, Shlomo Hareli, Miriam Elbaz, Itzhak Hayim Iluz, Svetlana Bunimovich-Mendrazitsky . BCG and IL − 2 model for bladder cancer treatment with fast and slow dynamics based on SPVF method—stability analysis. Mathematical Biosciences and Engineering, 2019, 16(5): 5346-5379. doi: 10.3934/mbe.2019267
    [4] Amer Hassan Albargi, Miled El Hajji . Mathematical analysis of a two-tiered microbial food-web model for the anaerobic digestion process. Mathematical Biosciences and Engineering, 2023, 20(4): 6591-6611. doi: 10.3934/mbe.2023283
    [5] Blessing O. Emerenini, Stefanie Sonner, Hermann J. Eberl . Mathematical analysis of a quorum sensing induced biofilm dispersal model and numerical simulation of hollowing effects. Mathematical Biosciences and Engineering, 2017, 14(3): 625-653. doi: 10.3934/mbe.2017036
    [6] Urszula Foryś, Jan Poleszczuk . A delay-differential equation model of HIV related cancer--immune system dynamics. Mathematical Biosciences and Engineering, 2011, 8(2): 627-641. doi: 10.3934/mbe.2011.8.627
    [7] Swadesh Pal, Malay Banerjee, Vitaly Volpert . Spatio-temporal Bazykin’s model with space-time nonlocality. Mathematical Biosciences and Engineering, 2020, 17(5): 4801-4824. doi: 10.3934/mbe.2020262
    [8] Awatif Jahman Alqarni, Azmin Sham Rambely, Sana Abdulkream Alharbi, Ishak Hashim . Dynamic behavior and stabilization of brain cell reconstitution after stroke under the proliferation and differentiation processes for stem cells. Mathematical Biosciences and Engineering, 2021, 18(5): 6288-6304. doi: 10.3934/mbe.2021314
    [9] Boumediene Benyahia, Tewfik Sari . Effect of a new variable integration on steady states of a two-step Anaerobic Digestion Model. Mathematical Biosciences and Engineering, 2020, 17(5): 5504-5533. doi: 10.3934/mbe.2020296
    [10] Pei Yu, Xiangyu Wang . Analysis on recurrence behavior in oscillating networks of biologically relevant organic reactions. Mathematical Biosciences and Engineering, 2019, 16(5): 5263-5286. doi: 10.3934/mbe.2019263
  • Early and successful myocardial reperfusion with primary percutaneous coronary intervention (pPCI) is the optimal therapy for patients presenting with ST segment elevation myocardial infarction (STEMI). Despite successful epicardial reopening of the infarct related artery, myocardial perfusion may not be restored in up to 40-50% of patients. This phenomenon, referred to as no-reflow (NR), recognizes several pathogenetic components including distal atherothrombotic embolization, ischaemic injury, reperfusion damage, intramyocardial hemorrhage and individual susceptibility of coronary microcirculation. However the complexity of pathogenesis remains still unclear. Moreover, cause NR plays a crucial role in patients prognosis, accurate detection is critical and multiple novel diagnostic modalities has been recently assessed.The NR phenomenon represents a challenge in the management of STEMI patients and has recently captured a growing interest of both basic scientists and interventional cardiologists. Although relevant efforts to transfer into real world practice new therapeutic strategies, to date there is still weak evidence of clinical improvement in this setting. Several strategies of prevention and treatment of NR have been proposed in the clinical arena including pharmacological and mechanical interventions. Nevertheless, the complexity of the phenomenon makes extremely unlikely for a single therapy to be effective. Understanding the interaction between the components of this pathway, along with exploring newer and more effective agents may enable patients to be treated with the most appropriate therapy.



    1. Introduction

    The brain is an organ with high energy needs. While it represents only 2% of the body weight it grabs at least 20% of its total energy needs [9]. The consumed energy can come from many forms such as glutamate, glucose, oxygen and also lactate [3]. Energy is necessary to support neural activity. Gliomas are the most frequent primary brain tumors (more than 50% of brain cancer cases according to the ICM institute). Like other cancers, they lead to alterations of cells' energy management. In particular, lactate creation, consumption, import and export of a glioma cell seem to play a key role in the cancer development [5]-[11]. Today, neuroimaging techniques allow an indirect and noninvasive measure of cerebral activity. It also enables measurement of various metabolic concentrations such as lactate and measurement of important biological parameters such as the relative cerebral blood volume (allowing relative cerebral blood flow calculations). But because energy management in healthy and tumoral cells and glioma growth can be difficult to observe and explain experimentally, we propose to use mathematical modeling to help to describe and understand cells energy changes.

    To the best of our knowledge, only a few mathematical models have been proposed to study lactate fluxes in the brain and the interconnections with energy, see [3] for example. We aim herein at analyzing a model first described in [2].

    Our paper is organized as follows. We first present the mathematical model proposed to describe the mechanisms of interest. We then investigate its well-posedness and derive bounds on the solutions. Indeed, such an analysis is necessary to justify how a mathematical model is well-adapted to a biological problem. We also analyze the limit model and study its steady state. Bounds on the solutions are important as they are related with the viability domain of the cell. Furthermore, as mentioned in [8], a therapeutic perspective is to have the steady state outside the viability domain where cell necrosis occurs. Additionnally, we present numerical simulations with different values of the small parameter $\varepsilon$ and compare them with experimental data. We finally discuss our results.


    2. Mathematical modeling

    The present model is reduced in order to follow in a simpler way lacate kinetics between a cell and the capillary network in its neighborhood. It is built in vivo which means that we have to consider loss and input terms for both intracellular and capillary lactate concentrations. We denote by $u_{\varepsilon}$ the intracellular lactate concentration and $v_{\varepsilon}$ the capillary lactate concentration where $\varepsilon$ stands for the volume separating the compartments. They are given in mM. One of the main parameters in the model is $\varepsilon$. Indeed to manage the blood flow, vessels dilate and modify their volume. We cannot model this phenomenon in a simple mathematical way. It is thus important to know how variations of their volume correlated with variations of $\varepsilon$ impact the whole dynamics.

    First, there is a lactate cotransport through the brain blood. It is taken into account by a simplified version of an equation for carrier-mediated symport. This nonlinear term depends on the maximum transport rate between the blood and the cell $T>0$ and the modified Michaelis-Menten positive constant for both intracellular and capillary lactate concentrations ($k$ and $k'$ respectively).

    Then a cell can equally produce and consume lactate, but also export surplus lactate to neighboring cells. We denote by $J$ the balance sheet of the whole phenomenon. The function $J$ is a nonnegative function depending on $t$ and $u_{\varepsilon}$ seen as a regulatory term. It is assumed to be bounded by a constant $B_J$ and Lipschitz continuous.

    Next there is a blood flow contribution to capillary lactate depending on both arterial and venous lactates. We denote by $L>0$ the arterial lactate concentration. We also define the blood flow $F$. The function $F$ is a positive bounded continuous function ($F_1 <F <F_2$) seen as a forcing term.

    Finally, we have the following ODE's, for $t \in \mathbb{R}^+$:

    $ uε(t)=J(t,uε(t))T(uε(t)k+uε(t)vε(t)k+vε(t)),
    $
    (2.1)
    $ εvε(t)=F(t)(Lvε(t))+T(uε(t)k+uε(t)vε(t)k+vε(t)).
    $
    (2.2)

    The initial condition is given by :

    $(u_{\varepsilon}(0);v_{\varepsilon}(0)) = (\bar{u}_0;\bar{v}_0) \in \mathbb{R}^+\times \mathbb{R}^+.$

    The model is biologically described in [2], to which we refer the interested readers for a better understanding of this process.

    Figure 1. Schematic representation of lactate exchanges in a local brain part. There is a cotransport through the brain-blood barrier, a blood flow, cell creation and consumption and interactions between a cell and its neighborhood. Interactions are described in the main text.

    3. The case $\varepsilon>0$

    Well-posedness. Recall that an ODE system $x'(t) = f(t, x(t))$ on $\mathbb{R}^n$, $x = [x_1, \cdots, x_n]$, $f = [f_1, \cdots, f_n]$, is called quasipositive if the condition :

    $x \geqslant 0, x_k = 0 \Rightarrow f_k(t, x)\geqslant 0$

    is verified for all $k = 1, \cdots, n$. System (2.1)-(2.2) obviously is quasipositive. Hence solutions with nonnegative initial data $(\bar{u}_0;\bar{v}_0)$ remain in $(\mathbb{R}^{+})^{2}$ for all positive times.

    Since we have for nonnegative $u_1$ and $u_2$ :

    $|{\frac{u_1}{k+u_1}-\frac{u_2}{k+u_2}}| = \frac{k|{u_2-u_1}|}{(k+u_1)(k+u_2)} \leqslant \frac{|{u_2-u_1}|}{k}, $

    then we can rewrite (2.1)-(2.2), setting

    $X(t):=(uε(t);vε(t)),
    $

    to have $\forall t \in \mathbb{R}^+$ :

    $X'(t) = H(t, X(t)), ~~~~~~~~~ X(0) = X_0, $

    where $H$ is globally Lipschitz continuous with respect to the second variable. We finally conclude, thanks to the Cauchy-Lipschitz theorem, that we have existence and uniqueness of the solution to the system $\forall t \in \mathbb{R}^+$.

    Bounds on the solution. By means of (2.2), we have $\forall t \in \mathbb{R}^+$,

    $v_{\varepsilon}'(t) \leqslant -\frac{F_1 v_{\varepsilon}(t)}{\varepsilon}+\frac{F_2L}{\varepsilon}+\frac{T}{\varepsilon}, $

    which implies, using Gronwall's lemma, that

    $v_{\varepsilon}(t) \leqslant \exp (\frac{-F_1 t}{\varepsilon})\bar{v}_0+\int_0^t \exp (\frac{-F_1 (t-s)}{\varepsilon})\frac{T+F_2L}{\varepsilon}ds, $

    or equivalently,

    $v_{\varepsilon}(t) \leqslant \exp (\frac{-F_1 t}{\varepsilon})\bar{v}_0+\frac{T+F_2L}{F_1}(1- \exp (\frac{-F_1 t}{\varepsilon})).$

    One can see, using the above formula, that we have $\forall t \in \mathbb{R}^+$,

    $v_{\varepsilon}(t) \leqslant \max(\bar{v}_0, \frac{T+F_2L}{F_1}): = B_v. \label{Bv} $

    Theorem 3.1. We can exhibit a sufficient, but not necessary, condition to ensure a bound on $u_{\varepsilon}$. When it exists, let $B_J \in \mathbb{R}$ be such that :

    $\forall (t, x) \in \mathbb{R}^2, \ J(t, x) \leqslant B_J$

    and :

    $BJ<T(1Bvk+Bv)BJ(k+Bv)<Tk.(C2.1)
    $

    In that case, we have, setting $z = \frac{B_v}{k'+B_v}+\frac{B_J}{T}$ and $\forall t \in \mathbb{R}^+$ :

    $ uε(t)max(kz1z,ˉu0):=Bu.
    $
    (3.1)

    Remark 1. Condition $(C_{2.1})$ is related to the equation $f(x) = 0$ with $f(x) = B_J-\frac{Tx}{k+x}+\frac{TB_v}{k'+B_v}$ for which a positive solution exists if and only if $B_J <T(1-\frac{B_v}{k'+B_v})$, i.e. $(C_{2.1})$ holds. From a biological point of view, this condition means that at each time the lactate uptake by a cell (from itself or its neighborhood) cannot be larger than the lactate it can purge through the blood. Otherwise, the cell lactate concentration increase may not be limited.

    Proof. Equation (2.1) gives $\forall t \in \mathbb{R}^+$ :

    $u_{\varepsilon}'(t) \leqslant B_J+ T\frac{B_v}{B_v+k'}-T\frac{u_{\varepsilon}(t) }{k+u_{\varepsilon}(t) }.$

    We set $z = \frac{B_v}{k'+B_v}+\frac{B_J}{T}$ and have, thanks to (C$_{2.1}$) :

    $1-z = \frac{(k'+B_v)T}{(k'+B_v)T}-\frac{B_v(T+B_J)+k'B_J}{(k'+B_v)T} = \frac{k'T-B_J(k'+B_v)}{(k'+B_v)T} > 0.$

    Let $t \in \mathbb{R}^+$ be such that:

    $u_{\varepsilon}(t) > \frac{kz}{1-z}.$

    Then,

    $u_{\varepsilon}(t)(1-\frac{B_v}{k'+B_v}-\frac{B_J}{T}) > k(\frac{B_v}{k'+B_v}+\frac{B_J}{T}), $

    which yields

    $B_J+ T\frac{B_v}{B_v+k'}-T\frac{u_{\varepsilon}(t)}{k+u_{\varepsilon}(t)} < 0, $

    hence

    $ u_{\varepsilon}'(t) < 0. $

    We finally deduce that

    $uε(t)max(kz1z,ˉu0).
    $

    Remark 2. This condition on an upper bound on $J$ is sufficient but not necessary. We can actually also consider functions $J$ which do not satisfy (C$_{2.1}$) but for which, when $u_{\varepsilon}$ is large, we can exhibit a better upper bound satisfying (C$_{2.1}$). It is thus sufficient to write that $u_{\varepsilon}$ is bounded from above with a mild (C$_{2.1}$) condition. For example, we can take $J = J_{test}$ such that, $\forall (x, s) \in \mathbb{R}^+\times\mathbb{R}^+$ :

    $J_{test}(s, x) = \underbrace{G_J}_{\text{creation}}-\underbrace{L_J}_{\text{ consumption}}+\underbrace{\frac{C_J}{\varepsilon_J+x}}_{\text{import}}, $

    for positive constants $G_J$, $L_J$, $C_j$ and $\varepsilon_J$ such that $G_J>L_J$ and $G_J <L_J+\frac{Tk'}{k'+B_v}$. The second condition means that the lactate creation of the cell is smaller than its consumption and purge through the blood, so that the cell is able to manage lactate excess. Then, for $x \geqslant \frac{C_j}{\frac{Tk'}{k'+B_v}-G_J+L_J} = N_{test}$, $J_{test}$ is bounded by $\frac{Tk'}{k'+B_v}$ and satisfies (C$_{2.1}$). We conclude that, setting $z = \frac{B_v}{k'+B_v}+\frac{B_J}{T}$, then $u(t) \leqslant \max(N_{test}, \frac{kz}{1-z}, \bar{u}_0)$, $\forall t \in \mathbb{R}^+$. Even though we cannot assert that such a function $J$ is biologically relevant, it is improbable to find relevant functions $J$ leading to a fatal lactate increase in the cell. In fact, it is logical to expect functions decreasing in $x$, since, when a cell has more substrate than necessary for it to live on its own, it does not have to import or create more.

    We have already proved that $u_{\varepsilon}$ and $v_{\varepsilon}$ are nonnegative functions. We can exhibit lower bounds by using the same method. Indeed, (2.2) gives, $\forall t \in \mathbb{R}^+$ :

    $v_{\varepsilon}'(t) \geqslant -\frac{F_2 v_{\varepsilon}(t)}{\varepsilon}+\frac{F_1L}{\varepsilon}-\frac{T}{\varepsilon}\frac{B_v}{k'+B_v}.$

    Then, if $\frac{F_1L-T\frac{B_v}{k'+B_v}}{F_2} \geqslant 0 $ and for $t \in \mathbb{R}^+$ such that

    $v_{\varepsilon}(t) \leqslant \frac{F_1L-T\frac{B_v}{k'+B_v}}{F_2}, $

    we have $v_{\varepsilon}(t)'\geqslant 0$, so that, $\forall t \in \mathbb{R}^+$ :

    $vε(t)min(ˉv0,F1LTBvk+BvF2).
    $

    If $\frac{F_1L-T\frac{B_v}{k'+B_v}}{F_2} \leqslant 0 $, we cannot find a positive lower bound on $v_{\varepsilon}$ and we keep $v_{\varepsilon} \geqslant 0$. Finally :

    $ vε(t)min(ˉv0,max(F1LTBvk+BvF2,0)):=Mv.
    $
    (3.2)

    Similarly, $\forall t \in \mathbb{R}^+$ :

    $uε(t)T(Mvk+Mvuεk+uε).
    $

    Then $u_{\varepsilon}(t)\leqslant M_v\frac{k}{k'}$ leads to $u'(t)\geqslant 0$. This shows that

    $ uε(t)min(ˉu0,Mvkk):=Mu.
    $
    (3.3)

    Remark 3. The upper bound $B_v$ on $v_{\varepsilon}$ can be derived even when the initial data $\bar{v}_0$ and $\bar{u}_0$ depend on $\varepsilon$ and are bounded with respect to this parameter. To do so, we use the same method, adapting the final step so that

    $v_{\varepsilon}(t) \leqslant \max( \underset{\varepsilon>0}{\sup{\bar{v}_0}}, \frac{T+F_2L}{F_1}) .$

    The lower bounds $M_v$ and $M_u$ can be obtained in the same way for initial data depending on $\varepsilon$.

    Stability of the equilibrium. For constant $J$ and $F$, an equilibrium for (2.1)-(2.2) has been found in [4] :

    $ ul:=k(JT+vlk+vl)1(JT+vlk+vl),
    $
    (3.4)
    $ vl:=L+JF.
    $
    (3.5)

    It has also been proven that this unique stationary point is a node, hence a locally stable equilibrium. However, this equilibrium does not always exist. For existence, the parameters need to satisfy :

    $ JT+LF+JF(k+L)+J<1J2+JF(L+k)TFk<0.
    $
    (3.6)

    Remark 4. We have already shown that $v_{\varepsilon}(t) \leqslant L+\frac{T}{F} = B_v$, $\forall t \in \mathbb{R}^+$. We verify that the equilibrium $v_l$ is such that $v_l\leqslant B_v$, which requires $J\leqslant T$. In fact, under $(2.7)$, $J > T$ implies:

    $J^2+JF(L+k')-TFk'> T^2+TF(L+k')-TFk' = T(T+FL) > 0.$

    Therefore, the contraposition leads to:

    $J^2+JF(L+k')-TFk'\leqslant 0 \text{ implies } J \leqslant T.$

    We fix all the parameters but $J$. Then, we wish to rewrite this condition by giving it in terms of $J$. In this way, we have :

    $\Delta_J = F^2(L+k')^2+4TFk'>0$

    and there is an equilibrium only when $J \in]J_b, J_h[$, where :

    $Jb:=12(F(L+k)ΔJ),Jh:=12(F(L+k)+ΔJ).
    $

    Knowing that $J$ is nonnegative, there are only two possible cases :

    1. $0 <J <J_h$ with one steady-state which is a node,

    2. $J>J_h$ with no steady-state.

    A therapeutic perspective is to have the steady state outside the viability domain [8]. Therefore playing on cell lactate intake could be worth exploring: a large $J$ involves an unbounded cell lactate concentration which leads to an exit of the cell viability domain and, finally, the glioma cell death.


    4. The case $\varepsilon=0$

    We now study the limit system for $\varepsilon = 0 $, $F(t): = F$, $J(t, x): = J$ constant, given $\forall~t \in \mathbb{R}^+$ by :

    $ u0(t)=JT(u0(t)k+u0(t)v0(t)k+v0(t)),
    $
    (4.1)
    $ 0=F(Lv0(t))+T(u0(t)k+u0(t)v0(t)k+v0(t)),
    $
    (4.2)

    together with the initial condition :

    $u_0(0) = \bar{u}_0 \in \mathbb{R}^+.$

    We first give some preliminary results and then establish bounds on the solutions and study the well-posedness of the system. We finally compare the original system (with $\varepsilon>0$) with this limit system (with $\varepsilon = 0$).

    Preliminaries. The function $v_{0}$ given by (4.2) is defined as long as $v_{0}(t)$ belongs to $I =]-\infty, -k'[~\cup~]-k', +\infty[: = I_1~\cup~I_2$ and is continuous. Taking $v_{0}(0) = \tilde{v}_0 \in I_2$, then $v_{0}(t) \in I_2$ $\forall~t \in \mathbb{R}^+$. It is biologically relevant to take $v_0(0) = \tilde{v}_0 $ as the positive root of (4.2) for $u_0(0) = \bar{u}_0$.

    We define the function $\varphi_c$, for any constant $c>0$, by :

    ${\varphi _c}\left\{ ]c,+[],T[sTsc+s.
    \right.$

    It is easy to see that $\varphi_c$ is a monotone increasing function with $\varphi_c(0) = 0$. We also define an inverse function of $\varphi_c$ :

    $\varphi _c^{ - 1}\left\{ [0,T[[0,+[zczTz.
    \right.$

    Furthermore, we introduce the function $\psi_c$ defined by :

    ${{\psi }_{c}}\left\{ ]c,+[R           sFs+φc(s),
    \right.$

    where $\psi_c$ is a bijection from $]-c, +\infty[$ onto $\mathbb{R}$. It can also be a bijection from $\mathbb{R}^+$ onto itself. Its derivative reads :

    $\psi_c'(s) = F+\frac{Tc}{(c+s)^2}.$

    Employing (4.2), we have :

    $\psi_{k'}(v_0(t)) = FL+\varphi_k(u_0(t)).$

    We rewrite (4.1)-(4.2) as :

    $ v0(t)=ψ1k(FL+φk(u0(t))):=Ψ(u0(t)),
    $
    (4.3)
    $ u0(t)=JT(u0(t)k+u0(t)Ψ(u0(t))k+Ψ(u0(t))):=G(t,u0(t)),
    $
    (4.4)

    and set, for $y\in[0, +\infty[$ :

    $Ψ1(y)=φ1k(ψk(y)FL).
    $

    A priori bounds on the solutions. Thanks to (4.4), we have :

    $G(t, 0) = J+\frac{T\psi_{k'}^{-1}(FL)}{k'+\psi_{k'}^{-1}(FL)}\geqslant J, $

    and the system is quasipositive : for an initial condition $\bar{u}_0\geqslant 0$, there holds $u_{0}(t)\geqslant 0$, $\forall t \in \mathbb{R}^+$. A fortiori, we have $v_{0}(t) = \Psi(u_{0}(t)) \geqslant 0$.

    Using (4.2), we find an upper bound on $v_0$, $\forall t \in \mathbb{R}^+$ :

    $ v0(t)L+TF:=Bv,0.
    $
    (4.5)

    We can also obtain an upper bound on $u_0$ using Theorem 2.1. When it exists, we call it $B_{u, 0}$.

    We now rewrite (4.2) as :

    $v_{0}(t)^2+v_{0}(t)(k'-L+\frac{T}{F}-z)-k'(L+z) = 0, $

    where $z = \frac{Tu_{0}(t)}{(k+u_{0}(t))F}\leqslant \frac{T}{F}$.

    Noting that $v_{0}$ is positive, $\forall t \in \mathbb{R}^+$, we have :

    $ v0(t)=12(z+LTFk+(TF+kLz)2+4k(L+z)).
    $
    (4.6)

    Well-posedness. Equation (4.4) gives :

    $u0(t)=JT(u0(t)k+u0(t)Ψ(u0(t))k+Ψ(u0(t))):=G(t,u0(t)).
    $

    Lemma 1. The function $\Psi$ is Lipschitz continuous in $u_0$, i.e. there exists $K_L>0$ such that for all $u_1, u_2 \in [0, +\infty], $

    $|{\Psi(u_1)-\Psi(u_2)}| \leqslant K_L |{u_1-u_2}|.$

    Proof. Let $u \in \mathbb{R}^+$. We know that :

    $Ψ(u)=1(Ψ1)(Ψ(u))
    $

    and :

    $|(Ψ1)(Ψ(u))|=|(φ1k)(ψk(Ψ(u))FL)ψk(Ψ(u)))|=|Tk(Tψk(Ψ(u))+FL)2(F+Tk(k+Ψ(u))2)|=|Tk(Tk+F(k+Ψ(u))2)(T+φk(u))2(k+Ψ(u))2|.
    $

    It follows from the above that $\Psi(u) = v$, with :

    $0=F(Lv)+T(uk+uvk+v)vFL+T=Bv,0,v0.
    $

    Therefore, $\Psi(u) = v \in [0, B_{v, 0}]$ and :

    $|Ψ(u)|=1|(Ψ1)(Ψ(u))|=|(T+φk(u))2(k+Ψ(u))2Tk(Tk+F(k+Ψ(u))2)|(T+Tuk+u)2(k+Ψ(u))24T2(k+Bv,0)2:=KL.
    $

    Consequently, $G(t, u_{0})$ is Lipschitz continuous in $u_{0}$. Therefore, thanks to the Cauchy-Lipschitz theorem, we have the existence and uniqueness of the solution to (4.4), $\forall t \in \mathbb{R}^+$. Finally we have existence and uniqueness for $v_0$, recalling that $\Psi$ is a bijection.

    Stability of the equilibrium. As proved in [3], (4.1)-(4.2) can have at most one equilibrium given under the above parameters condition. The Jacobian of the system at this point gives the eigenvalue :

    $\lambda: = -T \frac{k}{(k+u_l)^2} <0.$

    Therefore, $u_l$ is locally stable. Moreover, $\forall t \in \mathbb{R}^+$, $v(t) = \Psi(u(t))$, where $\Psi$ is a bijective function. Setting $z_l = \frac{J}{T}+\frac{v_l}{k'+v_l}$, we have :

    $Tulk+ul=Tkzl1zl1zlk=Tzl=TJT+Tvlk+vl=F(JF+LL)+Tvlk+vl=F(vlL)+Tvlk+vl.
    $

    Thus :

    $Fv_l+T\frac{v_l}{k'+v_l} = FL+T\frac{u_l}{k+u_l} \Leftrightarrow v_l = \Psi(u_l), $

    and the stationnary point $v_l$ is locally stable.

    Comparison between the original and the limit systems. We wish to bound the difference between $(u_{\varepsilon};v_{\varepsilon})$ solution to (2.1)-(2.2) with $F(t): = F$ and $J(t, x): = J$ and $(u_{0};v_{0})$ solution to (4.1)-(4.2), $\forall t \in \mathbb{R}^+$. To do so, we choose the same initial condition for $u_{\varepsilon}$ and $u_0$ :

    $u_{\varepsilon}(0) = u_0(0) = \bar{u}_0.$

    We set $u = u_{\varepsilon}-u_{0}$ and $v = v_{\varepsilon}-v_0$. Using (2.1), (2.2), (4.1) and (4.2), we have, $\forall~t \in \mathbb{R}^+$ :

    $ u(t)=T(kv(t)(vε(t)+k)(v0(t)+k)ku(t)(uε(t)+k)(u0(t)+k)),
    $
    (4.7)
    $ εv(t)=Fv(t)+T(ku(t)(uε(t)+k)(u0(t)+k)kv(t)(vε(t)+k)(v0(t)+k))εv0(t).
    $
    (4.8)

    It follows from the above that, $\forall~t \in \mathbb{R}^+$ :

    $u0(t)=JT(u0(t)k+u0(t)v0(t)k+v0(t))[JT,J+T],v0(t)Bv,0,
    $

    Therefore, differentiating (4.2), we find :

    $Fv0(t)=T(ku0(t)(k+u0(t))2kv0(t)(k+v0(t))2)v0(t)(F+kT(k+v0(t))2)=Tku0(t)(k+u0(t))2,
    $

    hence $\forall~t \in \mathbb{R}^+$ :

    $|{v_{0}'(t)}| \leqslant \frac{kT(J+T)}{(F+\frac{k'T}{(k'+B_{v, 0})^2})}: = \gamma.$

    Next, multiplying $(4.7)$ by $u(t)$ and $(4.8)$ by $v(t)$ gives, $\forall~t \in \mathbb{R}^+$ :

    $ 12ddt(u2(t))Tk|u(t)||v(t)|,
    $
    (4.9)
    $ ε12ddt(v2(t))+Fv2(t)Tk|u(t)||v(t)|+ε|v(t)|γ.
    $
    (4.10)

    Noting that

    $Tk|u(t)||v(t)|+ε|v(t)|γ=(Tk|u(t)|2F)(F2|v(t)|)+(|v(t)|F2)(2Fεγ)F2v2(t)+4T2Fk2u2(t)+4γ2Fε2
    $

    and

    $Tk|u(t)||v(t)|=(Tk|u(t)|2F)(F2|v(t)|)F2v2(t)+2T2Fk2u2(t),
    $

    summing (4.9) and (4.10) thus yields, $\forall~t \in \mathbb{R}^+$ :

    $ddt(u2(t)+εv2(t))(8T2Fk2+4T2Fk2)(u2(t)+εv2(t))+8γ2Fε2.
    $

    Noting finally that :

    $u^2(0) = 0 \text{ and }u^2(0)+\varepsilon v^2(0) = \varepsilon (\bar{v}_0-\Psi(\bar{u}_0))^2, $

    Gronwall's lemma gives, $\forall~t \in \mathbb{R}^+$ :

    $u2(t)+εv2(t)exp(T2tF(8k2+4k2))(ε(ˉv0Ψ(ˉu0))2+k2(J+T)2(F+kT(k+L+TF)2)22ε2(2k2+1k2))k2(J+T)2(F+kT(k+L+TF)2)22ε2(2k2+1k2).
    $

    Remark 5. In the particular case $\bar{v}_0 = \Psi(\bar{u}_0)$, we have $\forall t \in [0, t_m]$ :

    $u2(t)+εv2(t)(exp(T2tmF(8k2+4k2))1)2γ2ε2T2(2k2+1k2)
    $

    which yields that, on the finite time interval $[0, t_m]$,

    $ |u(t)|Ctmε,|v(t)|Ctmε.
    $
    (4.11)

    Remark 6. Setting $v_{0}(0) = \tilde{v}_1 \in I_1$ the negative root of (4.2) for $u_0(t) = \bar{u}_0$, we define a second solution to (4.1)-(4.2) for every $t \in \mathbb{R}^+$. We strongly think that we can study this degenerate system with similar mathematical tools, but this does not make sense from a biological point of view.


    5. Numerical simulations and comparison with experimental data

    In this section, we first present several numerical simulations with relevant values of our parameters. We also compare the numerical simulations with different values of $J$ and $\varepsilon$. We finally give and study experimental data. These simulations have been done with the Matlab software.

    Numerical illustration with nonconstant $J$ and $F$. We first consider the system given by (2.1)-(2.2). We expect that a cell manages its lactate concentration by means of its amount but not of the experiment's duration. Therefore we assume that it is biologically relevant to take a function $J$ that does not depend of $t$. Besides, we expect that a cell imports more lactate when its lactate concentration is low. In other words $J$ should be monotone decreasing in $x$. Under this hypothesis we choose :

    $J\left\{ R+R+   xGJLj+Cjx+εj,
    \right.$

    containing a creation term, a consumption term and an import term. This function $J$ is a bounded and Lipschitz continuous function which enjoys the mild (C$_{2.1}$) condition. We also define, as given in [1] :

    $F\left\{ \begin{array}{l}
    {\mathbb{R}^ + } \to {\mathbb{R}^ + }\\
    t \mapsto \left\{ \begin{array}{l}
    {F_0}(1 + {\alpha _f})\;\;\;{\rm{if}}\;\exists N \in\mathbb{N} /(N - 1){t_f} + {t_i}{\rm{ < }}t{\rm{ < }}N{t_f},\\
    \;\;\;\;\;\;\;\;\;\;\;\;{F_0}\;\;{\rm{if}}\;\;{\rm{not}}
    \end{array}
    \right. \end{array} \right.$

    The parameters for these two functions are given in Table 1.

    Table 1. Parameters for $F$ and $J$.
    ParameterValueUnit
    $F_0$0.012s$^{-1}$
    $\alpha_f$0.5 $1$
    $t_i$50 $s$
    $t_f$100 $s$
    $C_J$5.7*10$^{-5}$ $mM^2.s^{-1}$
    $\varepsilon_J$0.001 $mM$
    $G_J$0.002 $mM.s^{-1}$
    $L_J$0.001 $mM.s^{-1}$
     | Show Table
    DownLoad: CSV

    We also consider the parameters given in [2] and [8]. In that case, $(\bar{u}_0;\bar{v}_0) = (1.15;1)$ and the parameters values are given in Table 2.

    Table 2. Parameters values.
    ParameterValueUnit
    $T$0.01mM.s$^{-1}$
    $k$3.5mM
    $k'$3.5mM
    $L$0.3mM
    $\varepsilon$0.001s$^{-1}$
     | Show Table
    DownLoad: CSV

    The solutions $u_{\varepsilon}$ and $v_{\varepsilon}$ remain nonnegative, as shown in Figure 3. Here, we have an upper bound on $v_{\varepsilon}$ and J enjoys (C$_{2.1}$), so that $u_{\varepsilon}$ has an upper bound too. Thus, the intracellular and capillary lactate concentrations match with the mathematical analysis. At the beginning, there is a dip for the capillary lactate concentration. The fluctuations on $F$ are rapidly damped out as time grows.

    Figure 2. The functions $F$ and $J$; $F$ is a periodic function while $J$ is a monotone decreasing function of $u$.
    Figure 3. Intracellular and capillary lactate dynamics with nonconstant functions $J$ and $F$. On the left, the intracellular lactate trajectory is upper bounded. On the right, the capillary lactate trajectory is upper bounded too, but has an initial dip. At the bottom the orbit is typical of fast-slow systems.

    Numerical simulations with different values of $J$ and $\varepsilon$. We now assume that $J$ and $F$ are constant in order to compare (2.1)-(2.2) with (4.1)-(4.2). The parameters values are given in Table 3, following [2] and [8], and the simulations are displayed in Figure 4.

    Table 3. Parameters values.
    ParameterValueUnit
    $T$0.01mM.s$^{-1}$
    $k$3.5mM
    $k'$3.5mM
    $L$0.3mM
    $J$0.0057mM.s$^{-1}$
    $F$0.0272s$^{-1}$
    $\varepsilon$0.1s$^{-1}$
     | Show Table
    DownLoad: CSV
    Figure 4. Intracellular and capillary lactate dynamics with constant functions $J$ and $F$. The intracellular lactate trajectory (on the left) and the capillary lactate trajectory (on the right) are both upper bounded and reach the corresponding steady state. The trajectories for the original system (with $\varepsilon >0$) are also lower bounded. On the right top corner the capillary lactate of the original system has an initial dip, while it does not exist on the capillary lactate curve of the limit system (right bottom corner).

    Note that, in that case, we have shown the existence of an upper bound on $u$ and the presence of a locally stable steady state. The limit system has almost the same dynamics as the initial one. The notable difference is the presence of a hard initial dip for the dynamics of the capillary lactate with $\varepsilon>0$. This dip does not exist in the dynamics given by the limit system.

    Using the parameters values given in Table 3, we perform numerical simulations with various values of $\varepsilon$. The results are given in Figure 5.

    Figure 5. Dynamics for different values of $\varepsilon$. On the left intracellular; the lactate trajectories seem not to differ a lot. On the right, the value of $\varepsilon$ is related to the dip stiffness for the capillary lactate trajectories.

    While the intracellular lactate trajectories seem not to differ a lot, the capillary lactate trajectories show different initial dynamics. The smaller $\varepsilon$ is, the steeper the dip is up to $\varepsilon = 0$, where there is no dip.

    Remark 7. An approach based on singular perturbation theory has been made on this model by Lahutte-Auboin et al. [7,8]. There, the authors give a geometrical explanation for the initial lactate dip and prove the existence of a periodic solution of the fast-slow system under a repetitive sequence of identical stimuli. In addition, our approach gives an estimate on the rate of convergence with respect to the parameters, which is usually not the case with singular perturbation theory.

    Using the parameters given in Table 3, we now test different values for $J$. The results are given in Figure 6.

    Figure 6. Dynamics for different values for $J$. On the right, the intracellular lactate trajectories are divided into two groups : for $J \in \{1, 0.1, 0.01 \}$, the concentration seems to explode, while for $J \in \{0.001, 0.0001\}$, it seems more stable. On the right the capillary lactate trajectories are devided into these two groups. For the first one, we can see a dip, while, for the second one, the steady state is not quickly reached.

    There is a limit value of $J$, denoted by $J_{lim}$, such that there is an equilibrium only for $J <J_{lim}$. With these parameters values, we have :

    $J_{lim} = 0.00851 \text{ mM.s$^{-1}$}.$

    There are two types of dynamics : those with $J <J_{lim}$ for which there is a steady state and those with $J>J_{lim}$ for which the intracellular lactate trajectory explodes.

    Experimental data. In this section we compare typical results obtained by using the model (with constant $J$ and $F$) with in vivo data. This model is known to give good results when fitted to experimental data in small time variations (seconds) [2]. We want here to test its robustness on larger time variations (days).

    For each five patients we have four lactate concentration measures (only three for patient 1) separated from each other by more than $80$ days. Biological data were collected from patients exhibiting low grade gliomas (WHO grade 2) histologically proven, using monovoxel proton MR spectroscopy sequences performed on a same whole body 3 Tesla magnet (Verio, Siemens Ag) using specific 32 channels head coil. Raw data have been performed under the JMRUI software for appropriate quantification of metabolites, especially lactate concentration.

    We are unable to distinguish between capillary lactate and intracellular lactate using imaging data. Therefore lactate concentration measures are the sum of the capillary lactate and intracellular lactate concentrations.

    Because lactate concentrations variations are intrinsic and depend on lactate exchanges, we assume that it is relevant to adjust the initial values ($\bar{u}_0$ and $\bar{v}_0$) and the exchanges with neighboring cells ($J$) only. We give the other parameters values in Table 4.

    Table 4. Parameters values.
    ParameterValueUnit
    $T$0.1mM.d$^{-1}$
    $k$3.5mM
    $k'$3.5mM
    $L$0.3mM
    $F$0.0272d$^{-1}$
    $\varepsilon$0.1d$^{-1}$
     | Show Table
    DownLoad: CSV

    The results are given in Figure 7. Fitted values of $\bar{u}_0$, $\bar{v}_0$ and $J$ for each patient are given in Table 5.

    Figure 7. Lactate concentration changes in a local brain part. Lactate concentration is given in mM (vertical axis) and time in days (horizontal axis). The red dots stand for medical data values, while the model simulations are displayed in continuous lines. While the four first patients exhibit Grompertz growth of their brain lactate concentration, patient 5 lactate concentration decreases in time. All the dynamics simulations tend to the steady state given in section 2.
    Table 5. Fitted values of $\bar{u}_0$, $\bar{v}_0$ and $J$.
    Patient $\bar{u}_0$ (mM) $\bar{v}_0$ (mM) $J$ (mM.d$^{-1}$)
    $1$ $0.025$ $0.329$ $0.026$
    $2$ $0.017$ $0.320$ $0.010$
    $3$ $0.034$ $0.338$ $0.001$
    $4$ $0.146$ $0.460$ $0.036$
    $5$ $1.817$ $2.291$ $0.007$
     | Show Table
    DownLoad: CSV

    Our model (with constant $J$ and $F$) is consistent with biological data. it is able to predict what happens after a lactate spike, when the brain sets up a huge regulation to turn back to an acceptable lactate concentration.


    6. Discussion

    In this study we analyze a model for lactate kinetics first given in [2]. This model is a first step in view of a better understanding of lactate dynamics in the brain. Lactate has a key role in neuroenergetics. Therefore studying its dynamics in the brain is necessary to better understand the energetic breakdown which is observed, for example in tumors. This model is known to give good results when fitted with experimental data [2], [8]. However, to the best of our knowledge, no mathematical analysis has been made to show the existence and uniqueness of the solution and conditions for bounds on the solution, but also comparisons between the original and limit systems.

    In this paper, we study the original and limit systems and obtain existence, uniqueness and bounds on the solutions for the two systems. We also give a condition on $J$ which ensures the existence of a locally stable steady state. Moreover, we give an upper estimate on the difference between the solutions of the two systems. We also give several numerical simulations, for different values of $\varepsilon$ and $J$. Finally we confront the model with in vivo data.

    When confronted with imaging data from NMR spectroscopy and perfusion, the model provides good results. Because there are large time variations, we cannot ensure that all the parameters remain constant in time. Therefore constant parameters are not good for explaining hard changes on the lactate concentration dynamics such as shifting from a decreasing concentration to an increasing one. Despite this, they can explain what happens after a lactate spike.

    Differences in lactate dynamics suggest that there are several glioma profiles with different typical kinetics. This could indicate that non-agressive low grade gliomas show an increasing lactate concentration and then move to more agressive form (WHO Ⅱ+ to WHO Ⅲ+). At this stage the glioma will exhibit angiogenesis, modified proteins and altered transporters, which leads to fluctuating lactate kinetics [6]. This point should be considered as a critical one because of its therapeutical management consequences. Yet the patient should be referred to more agressive therapeutics such as radiotherapy or chemotherapy. Also the imaging control frequency should be restrained as well.

    As already mentioned in [10], an initial dip exists in the brain lactate dynamics. This dip could be mathematically explained by the different initial values of the capillary lactate concentration between the original and limit systems. Therefore the dip can be biologically explained by compartment volume modifications.

    It cannot be excluded that $J$ stands only because the model is build to explain a local brain part dynamics. Then lactate exchanges between cells and the extracellular space have to be better studied to find a biologically relevant function $J$ or other models with a different way to take these interactions into account. Despite this, the function $J$ is described here with minimal assumptions. Therefore, this allows us to use this analysis with further choices for $J$ or modified systems.

    Indeed one perspective is to build more complex and suitable models for brain metabolism. Adding oxygen and glucose dynamics to this model can be the next step in view of a more accurate description of energy dynamics in the brain. It could also be interesting to build a model with different cell types (such as astrocyte and neuron), for a better understanding of the brain fuel substrate fluxes.


    Acknowledgments

    The authors wish to thank an anonymous referee for her/his careful reading of the paper and helpful comments.


    [1] Hamm CW, Bassand JP, Agewall S, et al. (2011) ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation. Eur Heart J 32: 2999-3054. doi: 10.1093/eurheartj/ehr236
    [2] Rezkalla SH, Kloner RA (2008) Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory. Catheter Cardiovasc Interv 72: 950-957. doi: 10.1002/ccd.21715
    [3] Eeckhout E, Kern MJ (2001) The coronary no-reflow phenomenon: a review of mechanisms and therapies. Eur Heart J 22: 729-739 doi: 10.1053/euhj.2000.2172
    [4] Wu KC, Zerhouni EA, Judd RM, et al. (1998) Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 97: 765-772. doi: 10.1161/01.CIR.97.8.765
    [5] Brosh D, Assali AR, Mager A, et al. (2007) Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality. Am J Cardiol 99: 442-445. doi: 10.1016/j.amjcard.2006.08.054
    [6] Bolognese L, Carrabba N, Parodi G, et al. (2004) Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation 109: 1121-1126. doi: 10.1161/01.CIR.0000118496.44135.A7
    [7] Ndrepepa G, Tiroch K, Fusaro M, et al. (2010) A 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol 55: 2383-2389. doi: 10.1016/j.jacc.2009.12.054
    [8] Kloner RA, Ganote CE, Jennings RB (1974) The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest 54: 1496-1508. doi: 10.1172/JCI107898
    [9] Galiuto L, Lombardo A, Maseri A, et al. (2003) Temporal evolution and functional outcome of no reflow: sustained and spontaneously reversible patterns following successful coronary recanalisation. Heart 89: 731-737. doi: 10.1136/heart.89.7.731
    [10] Limbruno U, De CM, Pistolesi S, et al. (2005) Distal embolization during primary angioplasty: histopathologic features and predictability. Am Heart J 150: 102-108 doi: 10.1016/j.ahj.2005.01.016
    [11] Bahrmann P, Werner GS, Heusch G, et al. (2007) Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris undergoing elective percutaneous coronary interventions. Circulation 115: 600-608 doi: 10.1161/CIRCULATIONAHA.106.660779
    [12] Kleinbongard P, Bose D, Baars T, et al. (2011) Vasoconstrictor potential of coronary aspirate from patients undergoing stenting of saphenous vein aortocoronary bypass grafts and its pharmacological attenuation. Circ Res 108: 344-352 doi: 10.1161/CIRCRESAHA.110.235713
    [13] Tranum-Jensen J, Janse MJ, Fiolet WT, et al. (1981) Tissue osmolality, cell swelling, and reperfusion in acute regional myocardial ischemia in the isolated porcine. Circ Res 49: 364-381. doi: 10.1161/01.RES.49.2.364
    [14] Yellon DM, Hausenloy DJ (2007) Myocardial reperfusion injury. N Engl J Med 357: 1121-1135. doi: 10.1056/NEJMra071667
    [15] Paradies G, Petrosillo G, Pistolese M, et al. (2004) Decrease in mitochondrial complex I activity in ischemic/reperfused rat heart: involvement of reactive oxygen species and cardiolipin. Circ Res 94: 53-59. doi: 10.1161/01.RES.0000109416.56608.64
    [16] Petrosillo G, Di Venosa N, Moro N, et al. (2011) In vivo hyperoxic preconditioning protects against rat-heart ischemia/reperfusion injury by inhibiting mitochondrial permeability transition pore opening and cytochrome c release. Free Radic Biol Med 50: 477-483. doi: 10.1016/j.freeradbiomed.2010.11.030
    [17] Lefer AM, Tsao PS, Aoki N, et al. (1990) Mediation of cardioprotection by transforming growth factor-beta. Science 249: 61-64. doi: 10.1126/science.2164258
    [18] Furuichi K, Wada T, Iwata Y, et al. (2006) Interleukin-1-dependent sequential chemokine expression and inflammatory cell infiltration in ischemia-reperfusion injury. Crit Care Med 34: 2447-2455. doi: 10.1097/01.CCM.0000233878.36340.10
    [19] Basso C, Rizzo S, Thiene G (2010) The metamorphosis of myocardial infarction following coronary recanalization. Cardiovasc Pathol 19: 22-28. doi: 10.1016/j.carpath.2009.06.010
    [20] Collet JP, Montalescot G (2005) The acute reperfusion management of STEMI in patients with impaired glucose tolerance and type 2 diabetes. Diabetes Vasc Dis Res 2: 136-143. doi: 10.3132/dvdr.2005.021
    [21] Golino P, Maroko PR, Carew TE (1987) The effect of acute hypercholesterolemia on myocardial infarct size and the no-reflow phenomenon during coronary occlusion-reperfusion. Circulation 75: 292-298. doi: 10.1161/01.CIR.75.1.292
    [22] Ishihara M (2012) Acute hyperglycemia in patients with acute myocardial infarction. Cric J 76: 563-571.
    [23] Gibson CM, Ryan KA, Murphy SA, et al. (1998) Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction. The TIMI Study Group. Thrombolysis in myocardial infarction. J Am Coll Cardiol 34: 974-982.
    [24] Araszkiewicz A, Lesiak M, Grajek S, et al. (2007) Effect of microvascular reperfusion on prognosis and left ventricular function in anterior wall myocardial infarction treated with primary angioplasty. Int J Cardiol 114: 183-187. doi: 10.1016/j.ijcard.2006.01.057
    [25] Lepper W, Sieswerda GT, Vanoverschelde JL, et al. (2001) Predictive value of markers of myocardial reperfusion in acute myocardial infarction for follow-up left ventricular function. Am J Cardiol 88: 1358-1363. doi: 10.1016/S0002-9149(01)02113-0
    [26] Vicente J, Mewton N, Croisille P, et al. (2009) Comparison of the angiographic myocardial blush grade with delayed-enhanced cardiac magnetic resonance for the assessment of microvascular obstruction in acute myocardial infarctions. Catheter Cardiovasc Interv 74: 1000-1007. doi: 10.1002/ccd.22157
    [27] Uetani T, Amano T, Kumagai S, et al. (2009) Intracoronary electrocardiogram recording with a bare-wire system: perioperative ST-segment elevation in the intracoronary electrocardiogram is associated with myocardial injury after elective coronary stent implantation. JACC Cardiovasc Interv 2: 127-135. doi: 10.1016/j.jcin.2008.07.010
    [28] Mather AN, Fairbairn TA, Artis NJ, et al. (2011) Timing of cardiovascular MR imaging after acute myocardial infarction: effect on estimates of infarct characteristics and prediction of late ventricular remodeling. Radiology 261: 116-126. doi: 10.1148/radiol.11110228
    [29] Lund GK, Stork A, Saeed M, et al. (2004) Acute myocardial infarction: evaluation with first-pass enhancement and delayed enhancement MR imaging compared with 201Tl SPECT imaging. Radiology 232: 49-57. doi: 10.1148/radiol.2321031127
    [30] Nijveldt R, Beek AM, Hirsch A, et al. (2008) Functional recovery after acute myocardial infarction: comparison between angiography, electrocardiography, and cardiovascular magnetic resonance measures of microvascular injury. J Am Coll Cardiol 52: 181-189. doi: 10.1016/j.jacc.2008.04.006
    [31] Greaves K, Dixon SR, Fejka M, et al. (2003) Myocardial contrast echocardiography is superior to other known modalities for assessing myocardial reperfusion after acute myocardial infarction. Heart 89: 139-144. doi: 10.1136/heart.89.2.139
    [32] Tanaka A, Kawarabayashi T, Nishibori Y, et al. (2002) No-reflow phenomenon and lesion morphology in patients with acute myocardial infarction. Circulation 105: 2148-2152. doi: 10.1161/01.CIR.0000015697.59592.07
    [33] Watanabe T, Nanto S, Uematsu M, et al. (2003) Prediction of no-reflow phenomenon after successful percutaneous coronary intervention in patients with acute myocardial infarction: intravascular ultrasound findings. Circ J 67: 667-671. doi: 10.1253/circj.67.667
    [34] Wu X, Mintz GS, Xu K, et al. (2011) The relationship between attenuated plaque identified by intravascular ultrasound and no-reflow after stenting in acute myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. JACC Cardiovasc Interv 4: 495-502.
    [35] Tanaka A, Imanishi T, Kitabata H, et al. (2009) Lipid-rich plaque and myocardial perfusion after successful stenting in patients with non-ST-segment elevation acute coronary syndrome: an optical coherence tomography study. Eur Heart J 30: 1348-1355. doi: 10.1093/eurheartj/ehp122
    [36] Svilaas T, Vlaar PJ, van der Horst IC, et al. (2008) Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med 358: 557-567. doi: 10.1056/NEJMoa0706416
    [37] Frobert O, Lagerqvist B, Olivecrona GK, et al. (2013) TASTE Trial. Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med 369: 1587-1597.
    [38] Jolly SS, Cairns JA, Yusuf S, et al. (2015) TOTAL Investigators. Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med 372: 1389-1398.
    [39] Puymirat E, Aissaoui N, Cottin Y, et al. (2014) Effect of coronary thrombus aspiration during primary percutaneous coronary intervention on one-year survival (from the FAST-MI 2010 registry). Am J Cardiol 114: 1651-1657. doi: 10.1016/j.amjcard.2014.08.039
    [40] Kilic S, Ottervanger JP, Dambrink JH, et al. (2014) Myocardial Infarction Study Group. The effect of thrombus aspiration during primary percutaneous coronary intervention on clinical outcome in daily clinical practice. Thromb Haemost 111: 165-171.
    [41] Jones DA, Rathod KS, Gallagher S, et al. (2015) Manual thrombus aspiration is not associated with reduced mortality in patients treated with primary percutaneous coronary intervention: an observational study of 10,929 patients with ST-segment elevation myocardial infarction from the London Heart Attack Group. JACC Cardiovasc Interv 8: 575-584. doi: 10.1016/j.jcin.2014.11.021
    [42] Siudak Z, Mielecki W, Dziewierz A, et al. (2015) No long-term clinical benefit from manual aspiration thrombectomy in ST-elevation myocardial infarction patients. Data from NRDES registry. Catheter Cardiovasc Interv 85: E16-E22. doi: 10.1002/ccd.25572
    [43] De Rosa S, Cirillo P, De Luca G, et al. (2007) Rheolytic thrombectomy during percutaneous coronary intervention improves long-term outcome in high-risk patients with acute myocardial infarction. J Interv Cardiol 20: 292-298. doi: 10.1111/j.1540-8183.2007.00271.x
    [44] Mehta SK, Frutkin AD, Milford-Beland S, et al. (2007) Utilization of distal embolic protection in saphenous vein graft interventions (an analysis of 19,546 patients in the American College of Cardiology-National Cardiovascular Data Registry). Am J Cardiol 100: 1114-1118. doi: 10.1016/j.amjcard.2007.04.058
    [45] Baim DS, Wahr D, George B, et al. (2002) Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 105: 1285-1290.
    [46] Heusch G, Kleinbongard P, Bose D, et al. (2009) Coronary microembolization: from bedside to bench and back to bedside. Circulation 120: 1822-1836. doi: 10.1161/CIRCULATIONAHA.109.888784
    [47] Ali A, Cox D, Dib N, et al. (2006) Rheolytic thrombectomy with percutaneous coronary intervention for infarct size reduction in acute myocardial infarction: 30-day results from a multicenter randomized study. J Am Coll Cardiol 48: 244-252. doi: 10.1016/j.jacc.2006.03.044
    [48] Stone GW, Abizaid A, Silber S, et al. (2012) Prospective, randomized,multicenter evaluation of a polyethylene terephthalate micronet mesh-covered stent (MGuard) in ST-segment elevation myocardial infarction: the master trial. J Am Coll Cardiol S0735-1097: 04506-8.
    [49] Dudek D, Brener SJ, Rakowski T, et al. (2014) Efficacy of an embolic protection stent as a function of delay to reperfusion in st-segment elevation myocardial infarction (from the MASTER Trial). Am J Cardiol 114: 1485-1489. doi: 10.1016/j.amjcard.2014.08.007
    [50] Thiele H, Schindler K, Friedenberger J, et al. (2008) Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation 118: 49-57. doi: 10.1161/CIRCULATIONAHA.107.747642
    [51] Bartorelli AL, Trabattoni D, Galli S, et al. (1999) Successful dissolution of occlusive coronary thrombus with local administration of abciximab during PTCA. Catheter Cardiovasc Interv 48: 211-213. doi: 10.1002/(SICI)1522-726X(199910)48:2<211::AID-CCD20>3.0.CO;2-V
    [52] Kakkar AK, Moustapha A, Hanley HG, et al. (2004) Comparison of intracoronary vs. intravenous administration of abciximab in coronary stenting. Catheter Cardiovasc Interv 61: 31-34.
    [53] Stone GW, Maehara A, Witzenbichler B, et al. (2012) Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA 307: 1817-1826. doi: 10.1001/jama.2012.421
    [54] Thiele H, Wohrle J, Hambrecht R, et al. (2012) Intracoronary vs. intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial. Lancet 379: 923-931.
    [55] De Rosa S, Caiazzo G, Torella D, et al. (2012) Intracoronary abciximab reduces death and major adverse cardiovascular events in acute coronary syndromes: A meta-analysis of clinical trials. Int J Cardiol 7-5273(12)01631-2.
    [56] Van't Hof AW, Ten Berg J, Heestermans T, et al. (2008) Ongoing Tirofiban in myocardial infarction evaluation (On-TIME) 2 study group. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet 372: 537-546.
    [57] Authors/Task Force members, Windecker S, Kolh P, Alfonso F, et al. (2014) 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35: 2541-2619. doi: 10.1093/eurheartj/ehu278
    [58] Morikawa S, Takabe W, Mataki C, et al. (2002) The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells. J Atheroscler Thromb 9: 178-183. doi: 10.5551/jat.9.178
    [59] Oduncu V, Tanalp AC, Erkol A, et al. (2011) Impact of chronic pre-treatment of statins on the level of systemic inflammation and myocardial perfusion in patients undergoing primary angioplasty. Am J Cardiol 107: 179-185. doi: 10.1016/j.amjcard.2010.09.008
    [60] Iwakura K, Ito H, Kawano S, et al. (2006) Chronic pretreatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur Heart J 27: 534-539. doi: 10.1093/eurheartj/ehi715
    [61] Lyu T, Zhao Y, Zhang T, et al. (2013) Effect of statin pretreatment on myocardial perfusion in patients undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis. Clin Cardiol 36: E17-24. doi: 10.1002/clc.22169
    [62] Navarese EP, Kowalewski M, Andreotti F, et al. (2014) Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 113: 1753-1764. doi: 10.1016/j.amjcard.2014.02.034
    [63] Ross AM, Gibbons RJ, Stone GW, et al. (2005) A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 45: 1775-1780. doi: 10.1016/j.jacc.2005.02.061
    [64] Niccoli G, Rigattieri S, De Vita MR, et al. (2013) Open-label, randomized, placebo-controlled evaluation of intracoronary adenosine or nitroprusside after thrombus aspiration during primary percutaneous coronary intervention for the prevention of microvascular obstruction in acute myocardial infarction: the REOPEN-AMI study (Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction). JACC Cardiovasc Interv 6: 580-589. doi: 10.1016/j.jcin.2013.02.009
    [65] Nazir SA, Khan JN, Mahmoud IZ, et al. (2014) The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomised controlled trial.Trials 15: 371. doi: 10.1186/1745-6215-15-371
    [66] Ishii H, Ichimiya S, Kanashiro M, et al. (2005) Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST segment-elevation myocardial infarction. Circulation 112: 1284-1288. doi: 10.1161/CIRCULATIONAHA.104.530329
    [67] Vijayalakshmi K, Whittaker VJ, Kunadian B, et al. (2006) Prospective, randomized controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes. Heart 92: 1278-1284. doi: 10.1136/hrt.2005.075077
    [68] Michaels AD, Appleby M, Otten MH, et al. (2002) Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial. J Invasive Cardiol 14: 299-302.
    [69] Su Q, Li L, Liu Y (2013) Short-term effect of verapamil on coronary no-reflow associated with percutaneous coronary intervention in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Cardiol 36: E11-16. doi: 10.1002/clc.22143
    [70] Piot C, Croisille P, Staat P, et al (2008) Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 359: 473-481. doi: 10.1056/NEJMoa071142
    [71] Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, et al. (2007) A unicenter, randomized, double-blind, parallel-group, placebo-controlled study of Melatonin as an Adjunct in patients with acute myocaRdial Infarction undergoing primary Angioplasty TheMelatonin Adjunct in the acute myocaRdial Infarction treated with Angioplasty (MARIA) trial: study design and rationale. Contemp Clin Trials 28: 532-539. doi: 10.1016/j.cct.2006.10.007
    [72] Kloner RA, Hale SL, Dai W, et al. (2012) Reduction of ischemia/reperfusion injury with bendavia, a mitochondria-targeting cytoprotective Peptide. J Am Heart Assoc 1: e001644.
    [73] Kandzari DE, Hasselblad V, Tcheng JE, et al (2004) Improved clinical outcome with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. Am Heart J 147: 457-462. doi: 10.1016/j.ahj.2003.08.011
    [74] Amit G, Cafri C, Yaroslavtsev S, et al. (2006) Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial. Am Heart J 152: 887.e9-14.
  • This article has been cited by:

    1. A. Perrillat-Mercerot, C. Guillevin, A. Miranville, R. Guillevin, Using mathematics in MRI data management for glioma assesment, 2019, 01509861, 10.1016/j.neurad.2019.11.004
    2. Angélique Perrillat-Mercerot, Alain Miranville, Abramo Agosti, Elisabetta Rocca, Pasquale Ciarletta, Rémy Guillevin, Partial differential model of lactate neuro-energetics: analytic results and numerical simulations, 2021, 1477-8599, 10.1093/imammb/dqaa016
    3. Angélique Perrillat-Mercerot, Nicolas Bourmeyster, Carole Guillevin, Alain Miranville, Rémy Guillevin, Mathematical Modeling of Substrates Fluxes and Tumor Growth in the Brain, 2019, 67, 0001-5342, 149, 10.1007/s10441-019-09343-1
    4. Remy Guillevin, 2018, Chapter 5, 978-3-319-78924-8, 93, 10.1007/978-3-319-78926-2_5
    5. Lu Li, Alain Miranville, Rémy Guillevin, Cahn–Hilliard Models for Glial Cells, 2020, 0095-4616, 10.1007/s00245-020-09696-x
    6. Monica Conti, Stefania Gatti, Alain Miranville, Mathematical analysis of a model for proliferative-to-invasive transition of hypoxic glioma cells, 2019, 189, 0362546X, 111572, 10.1016/j.na.2019.111572
    7. Laurence Cherfils, Stefania Gatti, Alain Miranville, Rémy Guillevin, Analysis of a model for tumor growth and lactate exchanges in a glioma, 2020, 0, 1937-1179, 0, 10.3934/dcdss.2020457
    8. Hussein Raad, Laurence Cherfils, Cyrille Allery, Rémy Guillevin, Optimal control of a model for brain lactate kinetics, 2023, 18758576, 1, 10.3233/ASY-221823
    9. Laurence Cherfils, Stefania Gatti, Carole Guillevin, Alain Miranville, Rémy Guillevin, On a tumor growth model with brain lactate kinetics, 2022, 39, 1477-8599, 382, 10.1093/imammb/dqac010
    10. Hawraa Alsayed, Hussein Fakih, Alain Miranville, Ali Wehbe, On an Optimal Control Problem Describing Lactate Transport Inhibition, 2023, 0022-3239, 10.1007/s10957-023-02271-8
    11. Hussein Raad, Cyrille Allery, Laurence Cherfils, Carole Guillevin, Alain Miranville, Thomas Sookiew, Luc Pellerin, Rémy Guillevin, Simulation of tumor density evolution upon chemotherapy alone or combined with a treatment to reduce lactate levels, 2024, 9, 2473-6988, 5250, 10.3934/math.2024254
    12. Nour Ali, Hussein Fakih, Ali Wehbe, On a singular mathematical model for brain lactate kinetics, 2024, 0170-4214, 10.1002/mma.9898
    13. Laurence Cherfils, Stefania Gatti, Alain Miranville, Hussein Raad, Rémy Guillevin, Optimal control of therapies on a tumor growth model with brain lactate kinetics, 2024, 0, 1937-1632, 0, 10.3934/dcdss.2024032
    14. Giulia Cavalleri, Pierluigi Colli, Alain Miranville, Elisabetta Rocca, On a brain tumor growth model with lactate metabolism, viscoelastic effects, and tissue damage, 2026, 87, 14681218, 104419, 10.1016/j.nonrwa.2025.104419
    15. Grazia Policastro, Vincenzo Luongo, Luigi Frunzo, Nick Cogan, Massimiliano Fabbricino, A mechanistic mathematical model for photo fermentative hydrogen and polyhydroxybutyrate production, 2023, 20, 1551-0018, 7407, 10.3934/mbe.2023321
  • Reader Comments
  • © 2015 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(7161) PDF downloads(1116) Cited by(1)

Article outline

Figures and Tables

Figures(5)  /  Tables(1)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog